The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...
An estimated 12,000 children are born with thalassemia major, a severe form of the disease, in India each year, accounting ...
You most likely have beta thalassemia minor (one normal gene and one that causes low beta-cell-chain production), which consists of mild anemia and very small cells. This condition can look very ...
There were no serious adverse events or treatment-related mortalities. Evidence Rating Level: 2 (Good) Study Rundown: Transfusion-dependent β-thalassemia (TDT) is a condition that results in iron ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...
Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results